Can trimethoprim‑sulfamethoxazole (Bactrim) cause fever?

Can Bactrim Cause Fever?

Yes, Bactrim (trimethoprim-sulfamethoxazole) can cause fever as part of serious hypersensitivity reactions, including drug-induced fever, DRESS syndrome, and life-threatening anaphylactic-type reactions.

Mechanism and Clinical Presentation

Fever from Bactrim typically occurs through two distinct mechanisms:

Drug-Induced Fever (Hypersensitivity)

• Drug-induced fever usually develops after 7-10 days of treatment, though it can appear at any time during therapy or even after discontinuation 1
• The fever resolves rapidly after stopping the medication 1
• This represents a hypersensitivity reaction rather than infection 1

Severe Hypersensitivity Syndromes

• DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) presents with fever, diffuse skin rash, eosinophilia, lymphadenopathy, and potential multi-organ involvement including hepatic failure 2
• DRESS typically appears 2 weeks after starting TMP-SMX and may be associated with reactivation of latent HHV-6 infection 3
• Fever is a cardinal feature alongside cutaneous manifestations and hematologic abnormalities 2

Life-Threatening Acute Reactions

• Sudden fever with severe hypotension can occur within minutes to hours of re-challenge in patients with recent (days to weeks) prior exposure 4
• This reaction includes fever, hypotension, confusion, and may require intravenous fluid resuscitation and vasopressors 4
• Patients may develop diffuse pulmonary infiltrates and hypoxemia alongside fever 5

High-Risk Populations

HIV/AIDS Patients

• HIV-infected patients have a markedly increased incidence of adverse reactions to TMP-SMX, including fever 6
• In one study, 29 of 37 AIDS patients (78%) developed drug toxicity when treated with TMP-SMX for Pneumocystis pneumonia, with fever being a common manifestation 6
• Toxicity typically appeared after a median of 7.5 days of treatment 6
• The incidence of adverse reactions including fever is significantly higher in AIDS patients compared to non-AIDS patients 4

Other At-Risk Groups

• Patients with severe allergies or bronchial asthma have increased risk 4
• Elderly patients are at higher risk for hematologic changes and adverse reactions 4

Clinical Recognition and Management

Warning Signs Requiring Immediate Discontinuation

• Stop TMP-SMX immediately at the first appearance of skin rash or any sign of serious adverse reaction 4
• Clinical signs warranting discontinuation include: rash, pharyngitis, fever, arthralgia, cough, chest pain, dyspnea, pallor, purpura, or jaundice 4
• These may be early indications of severe reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, or hepatic necrosis 4

Diagnostic Approach

• In patients presenting with fever on TMP-SMX, consider drug-induced fever in the differential, especially after 7-10 days of therapy 1
• Evaluate for DRESS syndrome if fever is accompanied by rash, eosinophilia, lymphadenopathy, or elevated liver enzymes 2
• Rule out infectious causes, but recognize that negative bacterial cultures in a febrile patient on TMP-SMX may support drug-induced fever 5

Management Strategy

• Discontinue TMP-SMX immediately when drug-induced fever or hypersensitivity is suspected 4, 1
• For DRESS syndrome, administer high-dose systemic corticosteroids after drug withdrawal 2, 3
• For acute hypotension and fever, provide supportive care with intravenous fluids and vasopressors as needed 4, 5
• Patients typically respond rapidly to supportive care once the drug is stopped 5

Critical Pitfalls to Avoid

• Do not re-challenge patients who developed fever, rash, or other adverse reactions to TMP-SMX within the previous 6-8 weeks without extreme caution and close observation 5
• The presence or absence of previous adverse reactions does not predict subsequent severe reactions 5
• Do not mistake drug-induced rash for infection-related rash in patients being treated for tickborne rickettsial diseases, as this can delay appropriate treatment 7
• In patients with suspected tickborne rickettsial illness, sulfonamides like TMP-SMX are associated with increased disease severity and should be avoided 7

Special Considerations for Desensitization

• In rare cases where TMP-SMX is the only therapeutic option (e.g., Pandoraea colonization in cystic fibrosis), desensitization may be attempted after confirming drug-induced fever diagnosis 1
• Desensitization requires informed consent, premedication with acetaminophen and prednisone, and gradual dose escalation over 8 days 1
• This approach should only be considered when no therapeutic alternatives exist 1